Actuate Therapeutics to Present at The Citizens Life Sciences Conference
MWN-AI** Summary
Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for challenging cancers, will be presenting at the Citizens Life Sciences Conference. CEO Dan Schmitt's presentation is scheduled for March 10, 2026, at 8:25 a.m. ET in Miami Beach, FL. This conference presents a significant opportunity for investors and stakeholders to learn more about Actuate's pioneering efforts in cancer treatment, particularly through its lead investigational drug, elraglusib.
Elraglusib is a GSK-3 beta inhibitor designed to target oncogenic pathways that drive tumor growth and contribute to resistance against traditional therapies, such as chemotherapy. Notably, it also aims to enhance anti-tumor immunity by modulating various immune checkpoints and immune cell functions. As cancer treatments continue to evolve, Actuate's focus on high-impact, difficult-to-treat cancers positions it at the forefront of scientific innovation.
In addition to the presentation, Actuate’s management team will be available for one-on-one meetings with registered attendees to foster meaningful discussions about their strategies and clinical developments. Interested parties can access a live webcast of the presentation through the company's website, as well as a replay for 30 days post-event.
Actuate faces challenges common to biotech companies, notably the unpredictability of clinical outcomes and regulatory approvals, as outlined in their forward-looking statements. These statements underscore the company's caution in navigating its development pipeline and the associated risks.
For further details regarding their work, investors can visit Actuate’s website and social media platforms, as the company continues to share updates on its progress and vision in the fight against difficult-to-treat cancers.
MWN-AI** Analysis
Actuate Therapeutics (NASDAQ: ACTU) is strategically positioned in the clinical-stage biopharmaceutical sector, focusing on developing therapies for high-impact, difficult-to-treat cancers. As the company prepares to present at the Citizens Life Sciences Conference, it's essential to analyze its prospects and provide actionable market advice for investors.
Actuate’s lead investigational drug, elraglusib, is noteworthy for its mechanism of action as a GSK-3? inhibitor. By targeting critical molecular pathways, it may offer advantages in addressing tumor growth and resistance to standard therapies. The promising nature of elraglusib could attract attention from oncology-focused investors and institutional stakeholders, particularly if clinical data presented at the conference showcases potential efficacy or novel use cases.
However, potential investors must remain cautious. The clinical-stage status of Actuate inherently carries risks, including uncertain timelines for drug development, challenges in patient enrollment, and the possibility of unforeseen side effects that could impact regulatory approvals. Given Actuate's dependence on external capital to fuel further development—indicated by concerns over financial stability—investors should weigh these risks carefully against the potential upside.
Attending the conference or following the webcast could provide critical insights. One-on-one meetings with the management team could yield additional information on future development strategies, financial position, and key milestones. Investors should pay attention to how management addresses questions regarding competition and potential market entry strategies, as these factors will significantly influence the company’s trajectory.
In conclusion, while Actuate Therapeutics presents an intriguing investment opportunity with its innovative approach to cancer treatment, potential investors should remain vigilant regarding the inherent risks. Monitoring the outcomes of the upcoming conference will be crucial in making informed decisions moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3?), today announced that Dan Schmitt, President & CEO of the Company, will present at the Citizens Life Sciences Conference in Miami Beach, FL on Tuesday, March 10, 2026, at 8:25 a.m. ET.
The webcast of Mr. Schmitt’s presentation will be available at:
The Actuate management team will be available for one-on-one meetings with registered conference attendees.
A live link to the presentation will be located under “Events” in the Investors section of the Company’s website at www.actuatetherapeutics.com. A replay of the webcast will be available on Actuate’s website for 30 days following the presentation.
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3? inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function.
For additional information, please visit the Company’s website at www.actuatetherapeutics.com or follow us on LinkedIn, X, and Facebook.
Forward Looking Statements
This press release contains forward-looking statements about us, including our and other parties’ clinical trials and development plans, and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies, early clinical trials and sub-group studies are not necessarily predictive of future results and may not correlate with improved responses, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2026, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, and our Quarterly Reports on Form 10-Q, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media Contact
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310
FAQ**
How is Actuate Therapeutics Inc. (ACTU) leveraging its GSK-3? inhibition approach to differentiate its cancer therapies in both Chicago and Fort Worth's biopharmaceutical landscapes?
What local collaborations or partnerships does Actuate Therapeutics Inc. (ACTU) foresee developing in Chicago and Fort Worth to enhance its clinical trial outcomes?
In what ways might the general investment climate in Chicago and Fort Worth impact Actuate Therapeutics Inc. (ACTU)'s funding strategies for its drug development initiatives?
How does Actuate Therapeutics Inc. (ACTU) plan to address competition from other biopharmaceutical firms in both Chicago and Fort Worth as it progresses with its lead investigational drug, elraglusib?
**MWN-AI FAQ is based on asking OpenAI questions about Actuate Therapeutics Inc. (NASDAQ: ACTU).
NASDAQ: ACTU
ACTU Trading
2.21% G/L:
$3 Last:
63,004 Volume:
$2.89 Open:
